Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics

Int Clin Psychopharmacol. 2004 Jul;19(4):241-9. doi: 10.1097/01.yic.0000133500.92025.20.


Long-acting injectable risperidone was assessed in schizophrenia patients who were symptomatically stable on conventional depot antipsychotics and who were then switched to long-acting risperidone. Participants in this open-label, multicentre, 12-week trial had received flupenthixol decanoate, fluphenazine decanoate, haloperidol decanoate, or zuclopenthixol decanoate for 4 months or longer. Each was considered symptomatically stable by investigators. After receiving two cycles of their conventional depot antipsychotic during the run-in period, patients were switched to receive long-acting risperidone every 2 weeks for 12 weeks at an initial dose of 25 mg. This dose could be increased in 12.5-mg increments at 4-week intervals. Ninety-two percent of the patients received all six injections; 62% received the 25-mg dose throughout the treatment period. Adverse events related to movement disorders were reported in 3%. Severity of movement disorders decreased during long-acting risperidone treatment. Positive and Negative Syndrome Scale (PANSS) total and factor scores and scores on the Clinical Global Impressions severity scale were significantly reduced during treatment; 48% of these stable patients showed further symptom improvement (> or =20% decrease in PANSS score at endpoint). The results indicate that patients with schizophrenia who are symptomatically stable during treatment with a conventional depot antipsychotic can be safely and effectively switched to long-acting injectable risperidone without a prior transition to oral risperidone.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study

MeSH terms

  • Adult
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / adverse effects*
  • Antipsychotic Agents / therapeutic use*
  • Clopenthixol / adverse effects
  • Clopenthixol / analogs & derivatives*
  • Clopenthixol / therapeutic use
  • Delayed-Action Preparations
  • Dose-Response Relationship, Drug
  • Female
  • Flupenthixol / adverse effects
  • Flupenthixol / analogs & derivatives*
  • Flupenthixol / therapeutic use
  • Fluphenazine / adverse effects
  • Fluphenazine / analogs & derivatives*
  • Fluphenazine / therapeutic use
  • Haloperidol / adverse effects
  • Haloperidol / analogs & derivatives*
  • Haloperidol / therapeutic use
  • Humans
  • Injections, Intramuscular
  • Male
  • Middle Aged
  • Movement Disorders / etiology
  • Psychiatric Status Rating Scales
  • Risperidone / administration & dosage
  • Risperidone / adverse effects*
  • Risperidone / therapeutic use*
  • Schizophrenia / drug therapy*


  • Antipsychotic Agents
  • Delayed-Action Preparations
  • clopenthixol decanoate
  • flupenthixol decanoate
  • Clopenthixol
  • haloperidol decanoate
  • Flupenthixol
  • fluphenazine depot
  • Haloperidol
  • Risperidone
  • Fluphenazine